Trexquant Investment LP Invests $244,000 in Ascendis Pharma A/S (ASND)

Trexquant Investment LP bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 8,800 shares of the biotechnology company’s stock, valued at approximately $244,000.

A number of other large investors have also bought and sold shares of the company. Karp Capital Management Corp acquired a new stake in Ascendis Pharma A/S during the first quarter worth $203,000. Victory Capital Management Inc. acquired a new stake in Ascendis Pharma A/S during the first quarter worth $144,000. OppenheimerFunds Inc. acquired a new stake in Ascendis Pharma A/S during the first quarter worth $8,334,000. FMR LLC raised its stake in Ascendis Pharma A/S by 2.7% in the first quarter. FMR LLC now owns 3,238,720 shares of the biotechnology company’s stock worth $90,685,000 after buying an additional 86,188 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in Ascendis Pharma A/S during the first quarter worth $5,022,000. 64.35% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Ascendis Pharma A/S (NASDAQ ASND) opened at 27.90 on Monday. Ascendis Pharma A/S has a 1-year low of $17.15 and a 1-year high of $31.86.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.24. Ascendis Pharma A/S had a negative return on equity of 66.76% and a negative net margin of 2,977.70%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $0.78 million. During the same period in the previous year, the firm earned ($0.53) earnings per share. The firm’s quarterly revenue was down 61.4% compared to the same quarter last year. Analysts predict that Ascendis Pharma A/S will post ($3.56) earnings per share for the current year.

WARNING: This story was first posted by [[site]] and is the sole property of of [[site]]. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at [[permalink]].

ASND has been the topic of a number of research reports. J P Morgan Chase & Co initiated coverage on shares of Ascendis Pharma A/S in a report on Thursday, May 11th. They set an “overweight” rating and a $36.00 target price on the stock. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Wedbush reissued an “outperform” rating and set a $34.00 target price (down from $36.00) on shares of Ascendis Pharma A/S in a report on Wednesday, May 24th. Leerink Swann reduced their target price on shares of Ascendis Pharma A/S from $30.00 to $26.00 and set a “market perform” rating on the stock in a report on Thursday, May 25th. Finally, ValuEngine raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, May 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Ascendis Pharma A/S has a consensus rating of “Hold” and an average price target of $29.60.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).